Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma Inc (NASDAQ: LUMO) is a clinical-stage biotechnology company pioneering therapies for rare endocrine disorders, with a focus on pediatric growth hormone deficiencies. This page aggregates official press releases, clinical trial updates, and strategic developments directly from the company and verified sources.
Investors and stakeholders will find timely updates on LUMO’s pipeline progress, including its lead oral growth hormone secretagogue LUM-201, regulatory milestones, and collaborative research initiatives. The curated content spans clinical data disclosures, partnership announcements, and scientific presentations relevant to rare disease therapeutics.
Key categories include Phase 2 trial results, FDA communications, intellectual property updates, and research collaborations. All materials are sourced to ensure compliance with financial reporting standards and medical accuracy.
Bookmark this page for streamlined access to Lumos Pharma’s latest advancements in transforming treatment paradigms for underserved patient populations. Regularly updated to reflect the company’s evolving role in rare disease innovation.
Aviceda Therapeutics, a clinical-stage biotech company, has appointed Dr. Emmett T. Cunningham Jr. to its Board of Directors. Dr. Cunningham brings over 20 years of experience as a physician-scientist, healthcare entrepreneur, and investor, previously serving as Senior Managing Director at Blackstone Group.
Throughout his career, Dr. Cunningham has contributed to the FDA approval of ten therapeutics, including notable ophthalmic treatments. He previously held the position of Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, where he played a key role in developing Macugen®, the first VEGF-A inhibitor approved for specific eye conditions.
The appointment comes as Aviceda prepares to advance AVD-104 into pivotal trials for geographic atrophy, utilizing their proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform aimed at alleviating chronic, non-resolving inflammation.
Lumos Pharma (NASDAQ:LUMO) and Double Point Ventures (DPV) have successfully completed their previously announced tender offer. DPV acquired Lumos shares at $4.25 per share in cash plus one contingent value right (CVR) per share, representing a total equity value of approximately $38 million. The deal represents a 7.6% premium to Lumos's closing price on October 22, 2024.
The tender offer resulted in 6,544,417 shares (75.62% of outstanding shares) being validly tendered. Following the merger completion on December 12, 2024, Lumos Pharma will operate as a standalone business of DPV from its Austin, Texas headquarters. The company's stock has ceased trading on NASDAQ.
Lumos Pharma presented new analyses from Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials at ESPE 2024. The data showed sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) patients over 24 months. Results demonstrated significant increases in Annualized Height Velocity (AHV) from baseline 4.6 cm/yr to 7.8 cm/yr at 6 months, maintaining 7.3 cm/yr at 24 months. The studies also showed notable improvements in IGF-1 levels from 13.1 to 29.2 nmol/L and IGFBP-3 from 133.5 to 186.2 nmol/L over 24 months. Additional analysis revealed correlation between pulsatile growth hormone secretion patterns and growth responses to LUM-201 treatment.
Lumos Pharma (NASDAQ:LUMO) announced that two abstracts featuring analyses from their Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting (ESPE 2024). The presentations, scheduled for November 17-18, 2024 in Liverpool, UK, will focus on LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD). The abstracts will cover growth responses and hormone secretion patterns in PGHD patients over 12-24 months of treatment.
Lumos Pharma, Inc. (NASDAQ:LUMO) announced that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society (APPES 2024). The event will take place from October 2-5, 2024, in New Delhi, India.
The presentation, scheduled for October 3rd, will focus on the evaluation of oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD). Professor Paul Hofman, MD, from the Liggins Institute, University of Auckland, New Zealand, will deliver the presentation titled 'Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial'.
Lumos Pharma (NASDAQ:LUMO) announced the acceptance of an abstract for presentation at the XXXI Meeting of the Latin American Society of Paediatric Endocrinology (SLEP 2024) in Santiago, Chile. The abstract, titled 'LUM-201 Restores Growth Hormone Secretion and Promotes Growth in Moderate Pediatric Growth Hormone Deficiency (PGHD): Phase 2 Topline Results from OraGrowtH210 and OraGrowtH212 Trials', will be presented as an e-poster on September 13, 2024. This presentation will feature an updated analysis of data from Lumos Pharma's Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials, focusing on their therapeutic candidate for rare diseases.
Lumos Pharma (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focusing on rare disease therapeutics, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. The company's management will be available for one-on-one meetings on September 9th and 10th.
Key details include:
- An on-demand corporate presentation available from September 9th at 7:00 AM EDT
- A webcast accessible for 90 days after the event
- The presentation will also be available on Lumos Pharma's website
Investors can contact H.C. Wainwright sales representatives or Lumos Pharma's Investor Relations to schedule meetings with management during or after the conference.
Lumos Pharma (NASDAQ:LUMO) reported Q2 2024 financial results and provided a clinical update. Key highlights include:
1. Advancing plans for a Phase 3 placebo-controlled trial of LUM-201 in moderate pediatric growth hormone deficiency, expected to initiate in Q2 2025.
2. Cash position of $16.8 million as of June 30, 2024, sufficient to support operations into Q1 2025.
3. Q2 2024 net loss of $7.6 million, compared to $8.9 million in Q2 2023.
4. R&D expenses decreased to $4.6 million, while G&A expenses reduced to $3.7 million.
5. Presented new analyses of OraGrowtH212 Trial data at ENDO 2024, supporting LUM-201's unique mechanism of action.
Lumos Pharma (NASDAQ:LUMO), a late-stage biopharmaceutical company focusing on rare disease therapeutics, has announced it will report its second quarter 2024 financial results after market close on August 1, 2024. The company will host a conference call and webcast at 4:30pm ET the same day to discuss these results and provide updates on clinical and corporate activities.
The call will include a question-and-answer session following prepared remarks. Participants can join via phone or webcast, with dial-in registration available 15 minutes before the scheduled start time. A replay of the call will be accessible through the company's website after the event.
Lumos Pharma presented new analyses of its Phase 2 OraGrowtH212 trial at the ENDO 2024 meeting. The data reveals that oral LUM-201 significantly increased growth hormone (GH) secretion in children with moderate Pediatric Growth Hormone Deficiency (PGHD) over six months. The treatment restored GH levels to near-normal compared to healthy children, with lower GH exposure than traditional rhGH injections. This supports Lumos Pharma's plans for a Phase 3 trial. Results showed GH secretion increased from 0.19 to 0.36 μg/kg/12-hrs at 1.6 mg/kg/day dose and from 1.17 to 1.8 μg/kg/12-hrs for pulsatile GH. The data suggests a positive correlation between growth response and GH pulsatility patterns.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
